Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells

Chia Hsin Chang, Wei Ting Liu, Hui Chi Hung, Chia Yu Gean, Hong Ming Tsai, Chun Lin Su, Po Wu Gean

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Glioma stem cells (GSCs) contribute to tumor recurrence and drug resistance. This study characterizes the tumorigenesis of CD133+ cells and their sensitivity to pharmacological inhibition. Methods: GSCs from human U87 and rat C6 glioblastoma cell lines were isolated via magnetic cell sorting using CD133 as a cancer stem cell marker. Cell proliferation was determined using the WST-1 assay. An intracranial mouse model and bioluminescence imaging were used to assess the effects of drugs on tumor growth in vivo. Results: CD133+ cells expressed stem cell markers and exhibited self-renewal and enhanced tumor formation. Minocycline (Mino) was more effective in reducing the survival rate of CD133+ cells, whereas CD133+ cells were more sensitive to inhibition by the signal transducer and activator of transcription 3 (STAT3) inhibitor. Inhibition of STAT3 decreased the expression of CD133+ stem cell markers. The combination of Mino and STAT3 inhibitor synergistically reduced the cell viability of glioma cells. Furthermore, this combination synergistically suppressed tumor growth in nude mice. Conclusion: The results suggest that concurrent targeting of different subpopulations of glioblastoma cells may be an effective therapeutic strategy for patients with malignant glioma.

Original languageEnglish
Article number905
JournalBMC cancer
Volume17
Issue number1
DOIs
Publication statusPublished - 2017 Dec 29

Fingerprint

Glioblastoma
Glioma
STAT3 Transcription Factor
Growth
Pharmaceutical Preparations
Stem Cells
Neoplasms
Minocycline
Therapeutics
Neoplastic Stem Cells
Drug Resistance
Nude Mice
Cell Survival
Carcinogenesis
Survival Rate
Cell Proliferation
Pharmacology
Recurrence
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

@article{cfb54faedda14a41a846f08a49eacfe5,
title = "Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells",
abstract = "Background: Glioma stem cells (GSCs) contribute to tumor recurrence and drug resistance. This study characterizes the tumorigenesis of CD133+ cells and their sensitivity to pharmacological inhibition. Methods: GSCs from human U87 and rat C6 glioblastoma cell lines were isolated via magnetic cell sorting using CD133 as a cancer stem cell marker. Cell proliferation was determined using the WST-1 assay. An intracranial mouse model and bioluminescence imaging were used to assess the effects of drugs on tumor growth in vivo. Results: CD133+ cells expressed stem cell markers and exhibited self-renewal and enhanced tumor formation. Minocycline (Mino) was more effective in reducing the survival rate of CD133+ cells, whereas CD133+ cells were more sensitive to inhibition by the signal transducer and activator of transcription 3 (STAT3) inhibitor. Inhibition of STAT3 decreased the expression of CD133+ stem cell markers. The combination of Mino and STAT3 inhibitor synergistically reduced the cell viability of glioma cells. Furthermore, this combination synergistically suppressed tumor growth in nude mice. Conclusion: The results suggest that concurrent targeting of different subpopulations of glioblastoma cells may be an effective therapeutic strategy for patients with malignant glioma.",
author = "Chang, {Chia Hsin} and Liu, {Wei Ting} and Hung, {Hui Chi} and Gean, {Chia Yu} and Tsai, {Hong Ming} and Su, {Chun Lin} and Gean, {Po Wu}",
year = "2017",
month = "12",
day = "29",
doi = "10.1186/s12885-017-3924-y",
language = "English",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells. / Chang, Chia Hsin; Liu, Wei Ting; Hung, Hui Chi; Gean, Chia Yu; Tsai, Hong Ming; Su, Chun Lin; Gean, Po Wu.

In: BMC cancer, Vol. 17, No. 1, 905, 29.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells

AU - Chang, Chia Hsin

AU - Liu, Wei Ting

AU - Hung, Hui Chi

AU - Gean, Chia Yu

AU - Tsai, Hong Ming

AU - Su, Chun Lin

AU - Gean, Po Wu

PY - 2017/12/29

Y1 - 2017/12/29

N2 - Background: Glioma stem cells (GSCs) contribute to tumor recurrence and drug resistance. This study characterizes the tumorigenesis of CD133+ cells and their sensitivity to pharmacological inhibition. Methods: GSCs from human U87 and rat C6 glioblastoma cell lines were isolated via magnetic cell sorting using CD133 as a cancer stem cell marker. Cell proliferation was determined using the WST-1 assay. An intracranial mouse model and bioluminescence imaging were used to assess the effects of drugs on tumor growth in vivo. Results: CD133+ cells expressed stem cell markers and exhibited self-renewal and enhanced tumor formation. Minocycline (Mino) was more effective in reducing the survival rate of CD133+ cells, whereas CD133+ cells were more sensitive to inhibition by the signal transducer and activator of transcription 3 (STAT3) inhibitor. Inhibition of STAT3 decreased the expression of CD133+ stem cell markers. The combination of Mino and STAT3 inhibitor synergistically reduced the cell viability of glioma cells. Furthermore, this combination synergistically suppressed tumor growth in nude mice. Conclusion: The results suggest that concurrent targeting of different subpopulations of glioblastoma cells may be an effective therapeutic strategy for patients with malignant glioma.

AB - Background: Glioma stem cells (GSCs) contribute to tumor recurrence and drug resistance. This study characterizes the tumorigenesis of CD133+ cells and their sensitivity to pharmacological inhibition. Methods: GSCs from human U87 and rat C6 glioblastoma cell lines were isolated via magnetic cell sorting using CD133 as a cancer stem cell marker. Cell proliferation was determined using the WST-1 assay. An intracranial mouse model and bioluminescence imaging were used to assess the effects of drugs on tumor growth in vivo. Results: CD133+ cells expressed stem cell markers and exhibited self-renewal and enhanced tumor formation. Minocycline (Mino) was more effective in reducing the survival rate of CD133+ cells, whereas CD133+ cells were more sensitive to inhibition by the signal transducer and activator of transcription 3 (STAT3) inhibitor. Inhibition of STAT3 decreased the expression of CD133+ stem cell markers. The combination of Mino and STAT3 inhibitor synergistically reduced the cell viability of glioma cells. Furthermore, this combination synergistically suppressed tumor growth in nude mice. Conclusion: The results suggest that concurrent targeting of different subpopulations of glioblastoma cells may be an effective therapeutic strategy for patients with malignant glioma.

UR - http://www.scopus.com/inward/record.url?scp=85039707619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039707619&partnerID=8YFLogxK

U2 - 10.1186/s12885-017-3924-y

DO - 10.1186/s12885-017-3924-y

M3 - Article

C2 - 29284440

AN - SCOPUS:85039707619

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 905

ER -